Oncolytic adenovirus was engineered for the forced ectopic delivery of peptide-MHC ligand of T cell receptors (TCRs) to ...

PGV001, a personalized cancer vaccine, induced immune responses across various cancer types like breast and urothelial cancer ...

Ph.D., Ward-Coleman Chair in Cancer Research and Director of the Vaccine and Cell Therapy Laboratory, have tested a promising ...

Peptide-based vaccines deliver tumor-specific antigens to dendritic cells (DCs), triggering tumor-targeted T-cell responses. A peptide-peptide conjugate technology previously developed by researchers ...

Converging computational and laboratory technologies are helping anti-cancer immune responses hit their target more effectively.

BrightPath, formerly known as GreenPeptide, is moving beyond peptides to push the boundaries of cancer immunotherapy toward more personalized treatments. The ongoing battle against cancer has ...

As a cancer vaccine candidate developed using our ... neoantigens-encoding mRNAs are delivered into human body to produce neoantigen peptides, which activate neoantigen-specific T cell immune ...

Anixa Biosciences inks LoI with VERDI Solutions to develop artificial intelligence-guided personalized and off-the-shelf peptide vaccines for cancer: San Jose, Calif Friday, March ...